胆汁淤积的生物标志物研究进展 - 开云网页登录

主管：中华人民共和国教育部
主办：开云网页登录医学院附属瑞金医院
ISSN 1673-6087 CN 31-1978/R

内科理论与实践››2022,Vol. 17››Issue (01): 11-14.doi:10.16138/j.1673-6087.2022.01.003

• 专家论坛 •上一篇下一篇

胆汁淤积的生物标志物研究进展

蔡晓波, 王建香, 陆伦根

开云网页登录附属第一人民医院消化科,上海 200080

收稿日期:2021-11-25出版日期:2022-02-28发布日期:2022-07-25

Received:2021-11-25Online:2022-02-28Published:2022-07-25

摘要/Abstract

中图分类号:

R575

蔡晓波, 王建香, 陆伦根. 胆汁淤积的生物标志物研究进展[J]. 内科理论与实践, 2022, 17(01): 11-14.

参考文献18

[1]	Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease[J]. Gut, 2022, 71(1): 194-209. doi:10.1136/gutjnl-2021-324305 URL
[2]	中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1989-1999.
[3]	Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics[J]. Gut, 2016, 65(11): 1895-1905. doi:10.1136/gutjnl-2015-311292 URL
[4]	Kalas MA, Chavez L, Leon M, et al. Abnormal liver enzymes: a review for clinicians[J]. World J Hepatol, 2021, 13(11): 1688-1698. doi:10.4254/wjh.v13.i11.1688 URL
[5]	曹旬旬, 高月求, 张文宏, 等. 基于上海市住院慢性肝病患者胆汁淤积患病率的调查研究[J]. 中华肝脏病杂志, 2015, 23(8): 569-573.
[6]	Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis-a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323. doi:S0168-8278(17)32196-7pmid:28802875
[7]	Appanna G, Kallis Y. An update on the management of cholestatic liver diseases[J]. Clin Med (Lond), 2020, 20(5): 513-516.
[8]	Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver[J]. Mol Aspects Med, 2017, 56: 45-53. doi:10.1016/j.mam.2017.06.001 URL
[9]	Wu H, Chen C, Ziani S, et al. Fibrotic events in the progression of cholestatic liver disease[J]. Cells, 2021, 10(5): 1107. doi:10.3390/cells10051107 URL
[10]	李飞, 陆伦根. 胆汁淤积和黄疸的诊断与鉴别诊断[J]. 内科理论与实践, 2018, 13(6): 385-387.
[11]	Šarenac TM, Mikov M. Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients[J]. Front Pharmacol, 2018, 9: 939. doi:10.3389/fphar.2018.00939pmid:30319399
[12]	宋丹军, 潘家琪, 李鹏旭, 等. 溶血磷脂酰胆碱在肝脏疾病中的研究进展[J]. 中国药理学通报, 2014, 12: 1642-1646.
[13]	Reichert MC, Hall RA, Krawczyk M, et al. Genetic determinants of cholangiopathies: molecular and systems genetics[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4): 1484-1490. doi:10.1016/j.bbadis.2017.07.029 URL
[14]	Karlsen TH, Lammert F, Thompson RJ. Genetics of liver disease: from pathophysiology to clinical practice[J]. J Hepatol, 2015, 62(1 Suppl): S6-S14. doi:10.1016/j.jhep.2015.02.025 URL
[15]	García-Giménez JL, Seco-Cervera M, Tollefsbol TO, et al. Epigenetic biomarkers: current strategies and future challenges for their use in the clinical laboratory[J]. Crit Rev Clin Lab Sci, 2017, 54(7-8): 529-550. doi:10.1080/10408363.2017.1410520 URL
[16]	van der Kolk JH, Pacholewska A, Gerber V. The role of microRNAs in equine medicine: a review[J]. Vet Q, 2015, 35(2): 88-96. doi:10.1080/01652176.2015.1021186pmid:25695624
[17]	Kim YC, Jung H, Seok S, et al. MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice[J]. Hepatology, 2020, 71(6): 2118-2134. doi:10.1002/hep.30966 URL
[18]	Navaneethan U, Lourdusamy V, Gk Venkatesh P, et al. Bile proteomics for differentiation of malignant from benign biliary strictures[J]. Gastroenterol Rep (Oxf), 2015, 3(2): 136-143.

相关文章15

编辑推荐

Metrics

本文评价